Description

This product is a clear liquid, colorless to pale yellow.

Pharmacological Action

Pharmacodynamics：Enrofloxacin is a fluoroquinolone antibacterial agent with a broad spectrum of activity, exclusively used in animals. It is effective against Escherichia coli, Salmonella spp., Klebsiella spp., Brucella spp., Pasteurella spp., Actinobacillus pleuropneumoniae, Erysipelothrix rhusiopathiae, Proteus spp., Serratia marcescens, Corynebacterium pyogenes, Bordetella bronchiseptica, Staphylococcus aureus, Mycoplasma spp., Chlamydia spp., etc. Its activity against Pseudomonas aeruginosa and Streptococcus spp. is weaker, and it has only weak activity against anaerobes. It exhibits a significant post‑antibiotic effect against susceptible bacteria. The mechanism of antibacterial action of this product is the inhibition of bacterial DNA gyrase, thereby interfering with DNA replication, transcription, repair, and recombination, ultimately leading to the inability of bacteria to grow and multiply normally, resulting in their death.

Pharmacokinetics：After intramuscular injection, enrofloxacin is rapidly and completely absorbed, with a bioavailability of 91.9% in pigs and 82% in dairy cows. It is widely distributed in the animal body and penetrates well into tissues and body fluids; except for the cerebrospinal fluid, drug concentrations in almost all tissues are higher than those in plasma. Hepatic metabolism mainly involves de‑ethylation of the ethyl group on the 7‑piperazine ring to form ciprofloxacin, followed by oxidation and glucuronide conjugation. Excretion occurs primarily via the kidneys (by both tubular secretion and glomerular filtration), with 15–50% of the dose excreted unchanged in the urine. The elimination half‑life varies considerably among different animal species and routes of administration. After intramuscular injection, the elimination half‑life is 5.9 hours in dairy cows, 1.5–4.5 hours in sheep, and 4.6 hours in pigs.

Action and Use

Quinolone antibacterial agent. Used for the treatment of bacterial diseases and mycoplasma infections in livestock and poultry.

Dosage and Administration

Intramuscular injection: single dose, per 1 kg body weight — cattle, sheep, and pigs 0.1 ml; dogs, cats, and rabbits 0.1–0.2 ml. Administer once or twice daily for 2–3 consecutive days.

Adverse Reactions

(1) Causes degeneration of cartilage in young animals, affecting bone development and leading to lameness and pain.

(2) Digestive system reactions include vomiting, loss of appetite, diarrhea, etc.

(3) Skin reactions include erythema, pruritus, urticaria, and photosensitivity reactions.

(4) Hypersensitivity reactions, ataxia, and epileptic seizures have occasionally been reported in dogs and cats.

Precautions

(1) Has a potential excitatory effect on the central nervous system and may induce epileptic seizures; use with caution in dogs suffering from epilepsy.

(2) Use with caution in carnivores and animals with impaired renal function, as crystalluria may occasionally occur.

(3) This product is not suitable for dogs younger than 8 weeks of age.

(4) Resistant strains are increasing; do not use long-term at subtherapeutic doses.

Withdrawal Period

Withdrawal period: cattle and sheep 14 days, pigs 10 days, rabbits 14 days.

Specification

(1) 2 ml : 50 mg

(2) 5 ml : 0.125 g

(3) 10 ml : 0.25 g

(4) 100 ml : 2.5 g